

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): August 12, 2021**

**EyePoint Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-51122**  
(Commission  
File Number)

**26-2774444**  
(I.R.S. Employer  
Identification No.)

**480 Pleasant Street  
Watertown, MA 02472**  
(Address of Principal Executive Offices, and Zip Code)

**(617) 926-5000**  
Registrant's Telephone Number, Including Area Code  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001	EYPT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events.**

On August 12, 2021, EyePoint Pharmaceuticals, Inc. posted an updated corporate presentation on its website at [www.eyepointpharma.com](http://www.eyepointpharma.com). A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">Corporate Presentation, dated August 12, 2021</a>
104	Cover Page Interactive Data File (embedded within the inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**EYEPOINT PHARMACEUTICALS, INC.**

Date: August 17, 2021

By: /s/ George O. Elston  
Name: George O. Elston  
Title Chief Financial Officer and Head of Corporate Development

# Delivering Innovation to the Eye

Investor Presentation

August 2021



# Forward Looking Statements

Various statements made in this presentation are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the potential benefits of our partnerships and strategic alliances with other companies, as well as the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a vital, novel twice-yearly treatment for wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion; and our longer term financial and business goals, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the extent to which COVID-19 impacts our business; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ® and DEXYCU® and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; the success of current and future license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; termination or breach of current license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

## COMPANY OVERVIEW

# Proven technology driving pipeline growth

3 | EYEPOINT PHARMACEUTICALS

### Compelling pipeline focused on retinal disease

- EYP-1901 - potential twice yearly anti-VEGF (TKI) treatment in Phase 1 wet AMD trial
- YUTIQ50 – potential twice yearly treatment for posterior uveitis
- Evaluating additional molecules using Durasert for potential pipeline addition

### Durasert® - FDA validated drug delivery platform

- Sustained (zero-order kinetics) local delivery of drug product
- Provides constant and stable release of therapeutics in the eye over weeks, months or years
- Administered safely to thousands of patients' eyes across four FDA approved products including YUTIQ®


### Commercializing two FDA-approved products - YUTIQ® and DEXYCU®

- Solid Q2 net product revenues as COVID-19 restrictions eased across the US during 1H 2021

TECHNOLOGY

## DURASERT® Platform

Proven sustained release  
intraocular drug delivery



TECHNOLOGY

**DURASERT®**

**Proven sustained  
release delivery**



5 | EYEPOINT PHARMACEUTICALS

## Four FDA-approved products with multiple programs in development

- Single in-office intravitreal injection
- Continuous, stable release to the back of the eye provides consistent and reliable drug delivery over weeks, months or years
- Simple administration in physician's office

### Approved Products

- YUTIQ® (2018, EyePoint) - Posterior Segment Uveitis
- ILUVIEN® (2014, Alimera) - DME
- RETISERT® (2005, B&L) - Uveitis
- VITRASERT® (1996, B&L) - CMV retinitis

### Development Candidates

- EYP-1901 for Wet AMD
- YUTIQ® 50 for Posterior Segment Uveitis
- Undisclosed preclinical programs





PIPELINE

# Building on a Proven Platform

6 | EYEPOINT PHARMACEUTICALS

---

# Retinal disease focused pipeline

PROGRAM	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
<b>EYP-1901 - bioerodible Durasert with vorolanib</b> <ul style="list-style-type: none"> <li>• Wet AMD</li> <li>• Diabetic retinopathy</li> <li>• Retinal vein occlusion</li> </ul>				
<b>YUTIQ® 50 – FA insert for posterior chronic non-infectious uveitis</b>				
<b>Undisclosed Durasert programs</b>				

A person wearing a blue lab coat and glasses is sitting at a desk, reading a book. The background is slightly blurred, showing a stack of books on the right and a pair of glasses on the desk. The overall tone is professional and focused.


PIPELINE

## **EYP-1901 - Potential Twice a Year Anti-VEGF Treatment**

**Our goal is nothing short of transforming the treatment of wet AMD, diabetic retinopathy, and retinal vein occlusion**


PIPELINE

## EYP-1901



9 | EYEPOINT PHARMACEUTICALS

# Opportunity to transform the treatment of wet AMD



## The need...

Currently, wet AMD patients often lose vision despite anti-VEGF therapy due to undertreatment

## The EYP-1901 solution...


Potential twice yearly in-office injection of anti-VEGF therapy

- Anti-VEGF therapy (vorolanib) delivered via intravitreal injection using bioerodible Durasert
- Sustained, stable release may lead to better visual outcomes through steady receptor blocking

VEGF-vascular endothelial growth factor

PIPELINE

**EYP-1901**




VOROLANIB

DURASERT

# Real world need... today's wet AMD treatments still result in vision loss over time


RETROSPECTIVE STUDY OF 3350 RANIBIZUMAB AND 4300 AFLIBERCEPT TREATMENT-NAIVE EYES WITH WET AMD



Lotery et al., Eye (2017) 31, 1697–1706

PIPELINE

## EYP-1901



# The EYP-1901 solution

## EYP-1901


- Intravitreal delivery of vorolanib using a bioerodible formulation of Durasert®

## Vorolanib

- Tyrosine kinase inhibitor (TKI) studied as an oral therapy for wet AMD through Phase 2 with strong clinical signal and no significant ocular adverse events
- Blocks all 3 isoforms of VEGFR, the main driver of the proliferation of blood vessels that are the hallmark of wet AMD


PIPELINE

**EYP-1901**




# Effective blocking of VEGFR prevents neovascularization and loss of vision

VEGF SIGNALING PATHWAYS



PIPELINE

# EYP-1901



VOROLANIB

DURASERT

## A potent inhibitor of VEGFR

Vorolanib blocks VEGFR2 at the same level as sunitinib, a proven anti-VEGF therapy

### BIOCHEMICAL SELECTIVITY (IC50, ng/mL)


SUNITINIB	22.9
VOROLANIB	22.9

The inhibitor constant ( $K_i$ ) of sunitinib for VEGFR is reported to be low (5 ng/mL), an indication of strong inhibition. Since  $K_i$  is related to IC50, similar inhibition  $K_i$  is expected for vorolanib.



PIPELINE

**EYP-1901**



14 | EYEPOINT PHARMACEUTICALS

# Oral vorolanib clinical results – Phase 1

Demonstrated clinical activity in wet AMD

## Phase 1 trial design

- Open label, 24 weeks, dose escalation, no control, oral delivery; 80% of eyes enrolled previously treated; 4 eyes treatment naïve
- N=35; 25 completers


## Phase 1 results

- BCVA was maintained to within 4 letters of baseline at the 24-week endpoint, or improved in all but 1 participant
- 60% (15/25) of patients required no rescue injection while on oral vorolanib therapy
- Excluding the 50 mg low dose, 72% of completers required no Anti-VEGF injection through the duration of the study (6 months)
- Mean OCT thickness in completers was reduced by  $-50 \pm 97 \mu\text{m}$ ; Mean OCT thickness in treatment-naïve patients was reduced by  $\sim 80 \mu\text{m}$

OCT – ocular coherence tomography  
Study performed by Tyrogenex

PIPELINE

**EYP-1901**



VOROLANIB

DURASERT

15 | EYEPOINT PHARMACEUTICALS

# Oral vorolanib clinical activity in wet AMD Phase 2 trial

## Less rescue vs placebo for all doses with no ocular toxicity

For subjects followed $\geq$ 6 months	Placebo n=33	50 mg n=34	100 mg n=30	200 mg n=26
Median number of anti-VEGF injections*	9.0	6.1	5.8	4.6
Percent of Patients w/ no rescue	2.6	7.5	10.3	20.5

Strict pre-defined rescue criteria with anti-VEGF therapy

- Any increase in fluid on OCT compared to screening visit 2 (~14 days after an IVT injection)
- New or increased macular hemorrhage by fundus photography


In the placebo group, 12.5% of subjects with unilateral disease at baseline developed exudative AMD in their fellow eyes by 52 weeks, compared with 3.8% (1/26), 0%(0/27) and 0%(0/23) in the 50 mg, 100 mg, and 200 mg groups, respectively.

\* Normalized for number of months on study  
Study performed by Tyrogeix

# EYP-1901 pre-clinical results

PIPELINE

## EYP-1901




VOROLANIB

DURASERT

- 6-month rabbit GLP toxicology completed with no unexpected safety findings
- Efficacy and preliminary safety study completed in a laser CNV mini pig model
  - Results: dose-related activity and no observed toxicity
- Non-GLP rabbit PK and safety study demonstrated drug levels in vitreous and retina/choroid significantly above the IC50 for VEGFR2

PIPELINE

EYP-1901




VOROLANIB

DURASERT

17 | EYEPOINT PHARMACEUTICALS

# In-vivo cumulative % release of vorolanib in rabbits measured over ~8 months




$R^2$  for both doses indicates zero order release of drug at different dosing levels




# EYP-1901 Phase 1 Trial

PIPELINE

# EYP-1901




## Phase 1 DAVIO wet AMD clinical trial design




PIPELINE

**EYP-1901**



20 | EYEPOINT PHARMACEUTICALS


# Phase 1 DAVIO wet AMD clinical trial underway with interim data expected in Q4 2021



- UPDATE**
- Enrollment completion announced May 25, 2021
  - 17 patients in total dosed with EYP-1901
  - Positive 30-day safety results across all cohorts
  - On track for Q4 interim data read-out

PIPELINE

**EYP-1901**



VOROLANIB

DURASERT


21 | EYEPOINT PHARMACEUTICALS

## Positive 30-day safety results across all dose cohorts

- 17 patients enrolled across three dose cohorts
- No SAEs, ocular or systemic, were reported
- No reported adverse events related to intraocular inflammation
- No reported adverse events related to BCVA reduction
- No reported adverse events related to elevation of IOP
- No events of endophthalmitis, retinal detachment or migration into the anterior chamber reported
- The three subjects in Cohort 1 have been followed a minimum of six months with no reported SAEs

SAEs – serious adverse events  
BCVA – best corrected visual acuity  
IOP – intraocular pressure





PRODUCTS

# FDA Approved Commercial Products

22 | EYEPOINT PHARMACEUTICALS

---


## PRODUCTS



**CONTINUOUS CALM IN  
UVEITIS**

23 | EYEPOINT PHARMACEUTICALS

## Approved for the treatment of chronic non-infectious uveitis affecting the back of the eye



- Commercially launched in U.S. in 2019
- Patent protection to August 2027
- Constant and stable release of fluocinolone with Duraser<sup>®</sup> helps prevent uveitis flares for up to 3 years

### LICENSE AGREEMENTS

Alimera Sciences, Inc. has rights for non-infectious posterior uveitis in the EMEA

Rights for China, Hong Kong, Taiwan, Macau, Korea and certain SE Asia countries licensed to Ocumension with a royalty on sales payable to EyePoint

PRODUCTS



24 | EYEPOINT PHARMACEUTICALS

## Chronic non-infectious uveitis causes blindness with every flare

60K–100K patients are suffering from uveitis in the U.S.

### The need

- Flares can cause blindness
- 30,000 Americans become blind each year because of uveitis
- Uveitis lasts a lifetime and often affects people in middle age

### The YUTIQ answer

- 3-year continuous treatment in a single injection that controls flares and preserves eyesight
- Simple administration in the physician's office
- Gives patients and physicians the confidence that comes with three years of assured compliance

PRODUCTS




(fluocinolone acetonide  
intraocular implant) 0.18 mg

CONTINUOUS CALM  
IN UVEITIS

# Continuous 3-year delivery limits blindness-causing uveitis flares

## Time to recurrence of uveitis within 36 months




US Phase 3 Trial

PRODUCTS



28 | EYEPOINT  
PHARMACEUTICALS

# Customer demand returning from COVID shutdowns



## PRODUCTS



**DEXYCU**<sup>®</sup>  
(dexamethasone intraocular  
suspension) 9%

TARGET THE SITE

## Treatment of inflammation following ocular surgery

- Single long-lasting injectable treatment compared to low compliance eyedrop regimen
- Effective in preventing inflammation after cataract surgery with proven safety record
- Co-promoted with ImprimisRX, an established commercial organization in the cataract space



### LICENSE AGREEMENT

Rights for China, Hong Kong, Taiwan, Macau, Korea and certain SE Asia countries licensed to Ocumension with a royalty on sales payable to EyePoint

PRODUCTS



**DEXYCU**

(dexamethasone intraocular suspension) 9%

TARGET THE SITE

28 | EYEPOINT PHARMACEUTICALS

# The U.S. cataract surgery market is large and growing

3.8 million cataract surgeries in 2018

## The need

- As the baby boom generation ages, cataract surgery will become even more common

## The DEXYCU answer

- Today, eyedrops are the most common treatment after cataract surgery
- Patients forget to take their eye drops, leading to unnecessary complications
- Dexycu is injected into the eye at the time of surgery so compliance is not an issue

# Record customer demand in Q2 2021


## PRODUCTS



**DEXYCU**<sup>®</sup>  
(dexamethasone intraocular  
suspension) 9%

TARGET THE SITE

28 | EYEPOINT  
PHARMACEUTICALS





DELIVERING INNOVATION  
TO THE EYE

## Financial Summary

30 | EYEPOINT PHARMACEUTICALS

### **Solid cash position and growing revenues supporting cash runway**

- **\$127.6 million of Cash on June 30, 2021**
  - **\$8.7 million net product revenues in Q2 2021, a 136% increase over Q2 2020**
  - **\$15.5 million net product revenues in 1H 2021, an 85% increase over 1H 2020**
  - **Cash and anticipated cash from net product revenues funds planned operations through 2022**
-



**Delivering Innovation to the Eye**



